novartis ag eu drugs panel backs tasigna galvus combo novartis ag said the european unions drugs advisory body has recommended approval of tasigna a follow up treatment to gleevec the swiss drug makers second best selling drug the agency is also recommending approval of a pill that combines the companys new diabetes drug galvus with metformin the standard treatment novartis said tasigna is a new targeted cancer drug for patients with a form of the life threatening blood cancer chronic myeloid leukemia who are resistant or intolerant to treatment with gleevec novartis expects tasigna to eventually replace gleevec and plans to test its efficacy and safety in patients who havent yet been treated with gleevec 
